UBS Group’s Medicus Pharma MDCX Stock Holding History

UBS Group’s Portfolio MDCX Stock Details MDCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-809	Closed	-$18.6K	–	11300
2026 Q1	$18.6K	Buy	809 +544	+205%	+$28.4K	﹤0.01%	7991
2025 Q4	$20.2K	Buy	265 +126	+91%	+$13.5K	﹤0.01%	7767
2025 Q3	$16.1K	Sell	139 -480	-78%	-$60.2K	﹤0.01%	8293
2025 Q2	$92.5K	Buy	619 +194	+46%	+$38.7K	﹤0.01%	7302
2025 Q1	$79.1K	Buy	+425	New	+$66.7K	﹤0.01%	7229

Other funds holding MDCX

ICP

Interchange Capital Partners Pittsburgh, Pennsylvania $532M AUM 26.57% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $599M AUM 28.66% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

MHC

May Hill Capital Cohasset, Massachusetts $479M AUM 31.88% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wilmington Savings Fund Society Wilmington, Delaware $4.48B AUM 24.77% 1-Year Est. Return

UBS Group's MDCX Position: Q2 2026 in Review

UBS Group sold out of Medicus Pharma (MDCX) in Q2 2026, closing a stake of 809 shares — an estimated $18.6K sold.

UBS Group first reported a position in MDCX in Q1 2025 and held it in 5 quarters. The position peaked at $92.5K in Q2 2025. 23 funds tracked by Wall St. Rank hold MDCX as of Q2 2026.

UBS Group reported no remaining Medicus Pharma position as of Q2 2026 after selling out during the quarter.
UBS Group sold 809 Medicus Pharma shares in Q2 2026, an estimated $18.6K.
UBS Group first reported a position in Medicus Pharma in Q1 2025 and held it in 5 quarters.
UBS Group's Medicus Pharma position peaked at $92.5K in Q2 2025.
23 funds tracked by Wall St. Rank held Medicus Pharma as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.